Clinical trial Recruiting at 1 site Observational

Understanding Inhibitory Neurotransmission in Drug-Resistant Epilepsy

Official title: Functional Study of Inhibitory and Excitatory Neurotransmission in the Nervous Tissue Resected From Human Brain: Understanding New Molecular Mechanisms and Discovering New Therapeutic Targets to Cure Drug-resistant Epilepsy.

Run by Neuromed IRCCS · NCT05459090 · Data updated 2026-11-12

This study is testing how certain brain receptors work in people with drug-resistant epilepsy to see if new treatments can help manage their condition better.

More Drug Resistant Epilepsy trials

Quick facts

Study typeObservational
SexAll
Enrollment60 (estimated)
SponsorNeuromed IRCCS
Academic / other
Locations1 site (Pozzilli, Isernia)
StatusRecruiting
StartedJuly 29, 2022
Main results expectedFebruary 28, 2025
Study endsJuly 31, 2027
Registry record updatedAugust 2, 2022
Trial IDNCT05459090 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients diagnosed with drug-resistant temporal lobe epilepsy.

Probably not a fit

Patients whose temporal lobe epilepsy is caused by stroke, ischemia, cavernous angiomas, or meningiomas may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the functional alterations of GABA-A receptors in patients with drug-resistant temporal lobe epilepsy. The researchers will utilize patch-clamp recordings to characterize GABA-A mediated currents and identify the receptor subunit composition. Additionally, the study will explore the modulation of inhibitory neurotransmission through selective neuroactive molecules to enhance GABA release in the epileptic brain. The ultimate goal is to gain insights that could lead to new therapeutic strategies for managing epilepsy.

Why it matters

Potential benefit: If successful, this study could lead to the development of novel treatments for patients with drug-resistant epilepsy.

How similar studies have gone: While the approach of modulating GABA-A receptor function is established, the specific focus on drug-resistant epilepsy and the proposed methodologies may offer novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients with drug-resistant temporal lobe epilepsy.

Exclusion Criteria:

* Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.

Where it's running

  • IRCCS INM Neuromed
    Pozzilli, Isernia, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.